Author(s): Schwarzenbach H, Hoon DS, Pantel K
Abstract Share this page
Abstract DNA, mRNA and microRNA are released and circulate in the blood of cancer patients. Changes in the levels of circulating nucleic acids have been associated with tumour burden and malignant progression. In the past decade a wealth of information indicating the potential use of circulating nucleic acids for cancer screening, prognosis and monitoring of the efficacy of anticancer therapies has emerged. In this Review, we discuss these findings with a specific focus on the clinical utility of cell-free nucleic acids as blood biomarkers.
This article was published in Nat Rev Cancer
and referenced in Journal of Genetic Syndromes & Gene Therapy